Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC-Reference-Cited by-同舟云学术

Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC

Published:2024-05 Issue:5 Volume:35 Page:437-447
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Yu H.A.,Baik C.,Kim D.-W.,Johnson M.L.,Hayashi H.,Nishio M.,Yang J.C.-H.^ORCID,Su W.-C.,Gold K.A.,Koczywas M.,Smit E.F.^ORCID,Steuer C.E.,Felip E.,Murakami H.,Kim S.-W.,Su X.,Sato S.,Fan P.-D.^ORCID,Fujimura M.,Tanaka Y.,Patel P.,Sternberg D.W.,Sellami D.,Jänne P.A.

Publisher

Elsevier BV

Reference28 articles.

1. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Hendriks;Ann Oncol,2023

2. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies;Johnson;Lung Cancer,2022

3. Milestone analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy in metastatic non-small cell lung cancer trials: a meta-analysis;Blumenthal;JAMA Oncol,2017

4. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives;Rebuzzi;Crit Rev Oncol Hematol,2020

5. Third generation EGFR TKIs: current data and future directions;Tan;Mol Cancer,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody–drug conjugate development;Drug Discovery Today;2024-08

2. Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings;Cancers;2024-07-19

3. Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers;BioDrugs;2024-05-20

4. New ADCs bring new questions in EGFR NSCLC and beyond;Annals of Oncology;2024-05